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Background: Angiogenesis has been an attractive target for drug therapy. Aloin (AL), an natural compound derived
from Aloe barbadensis Miller leaves, has been shown to possess anti-cancer potential activities. However, its roles in
tumor angiogenesis and the involved molecular mechanism are unknown.
Method: To evaluate the antiangiogenic and anticancer activities of AL, endothelial cell scratch, modified Boyden
chamber inserts and tube formation assays were done in HUVECs, and MTT and Live-Dead assays were used to
determine the proliferation inhibition and apoptosis induction of colorectal cancer cells in vitro. The inhibition
effects of AL were further confirmed by a mouse xenograft model in vivo. The expression levels of STAT3 signaling
pathway and that mediated-target genes were measured in HUVECs and SW620 cells by Western blots.
Results: Here, we demonstrated that AL significantly inhibited HUVECs proliferation, migration and tube formation
in vitro. Western blotting showed that AL suppressed activation of VEGF receptor (VEGFR) 2 and STAT3
phosphorylation in endothelial cells. In addition, the constitutively activated STAT3 protein, and the expression
of STAT3-regulated antiapoptotic (Bcl-xL), proliferative (c-Myc), and angiogenic (VEGF) proteins were also
down-regulated in response to AL in human SW620 cancer cells. Consistent with the above findings, AL inhibited
tumor cell viability and induced cell apoptosis in vitro, and substantially reduced tumor volumes and weight
in vivo mouse xenografts, without obviously toxicity.
Conclusion: Our studies provided the first evidence that AL may inhibit tumor angiogenesis and growth
via blocking STAT3 activation, with the potential of a drug candidate for cancer therapy.
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Colorectal cancer (CRC) is the most common cause of
cancer-related mortality, with an estimated over 1.2 mil-
lion new diagnoses and 608,700 deaths worldwide [1].
Outcomes for patients with advanced CRC remain poor,
with the median survival of still less than 20 months [2].
The large number of cases and the continued poor sur-
vival rates in CRC underscores the need for new therapy
strategy.
The ability of tumors to progress to more malignant
phenotypes is dependent on the tumor microenviron-
ment. Angiogenesis, the development of new blood* Correspondence: tianlu0016@163.com
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reproduction in any medium, provided the orvessels from preexisting vascular bed, plays essential
roles in tumor growth, maintenance, and metastasis [3].
At present, inhibition of tumor angiogenesis is consid-
ered as a promising strategy for the treatment of cancer
[4]. Vascular endothelial growth factor (VEGF) is a po-
tent pro-angiogenic factor crucial for tumor vascular de-
velopment [5]. Vascular endothelial growth factor
receptor 2 (VEGFR2) is the primary receptor of VEGF
and the major mediator of VEGF-induced angiogenesis
pathways [6].When resting endothelial cells are acti-
vated, VEGFR2 signaling activates a number of down-
stream mediators and allows cells to proliferate, migrate,
invasive and finally differentiate to form capillary-like
structures [7]. Recently studies showed that among
VEGFR2-mediated signaling, especially signal transducer
and activator of transcription 3 (STAT3), has been. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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of human malignancies and is commonly associated with
a worse prognosis [8,9].
STAT3 belongs to a member of latent self-signaling
transcription factors in cytoplasm activated by certain
cytokines (e.g., IL-6) and growth factors (e.g., VEGF).
Upon activation, STAT3 homodimerizes and translocates
to the nuclear to subsequently modulates the transcrip-
tion of responsive genes encoding apoptosis inhibitors
(e.g., Bcl-xL, Bcl-2), proliferation regulatory proteins (e.
g., cyclin D1, c-myc), and inducers of angiogenesis (e.g.,
VEGF) [10], which were involved with cell proliferation,
survival, differentiation, apoptosis, metastasis, angiogen-
esis, host immune evasion, and drug resistance [11,12].
More recently, there is ample evidence in the literatures
that interference of constitutive STAT3 signaling suc-
cessfully results in an inhibition of growth and the in-
duction of apoptosis in tumors [10,13]. Given the
oncogenic function of STAT3 and promise of inhibiting
it, directly targeting STAT3 signaling cascade has been
an attractive therapeutic target for drug intervention to
treat cancer.
Recently agents that inhibited angiogenesis and
targeted STAT3 have been identified from plants, with
little side effects [13-15]. Aloin (AL; C21H22O9;
Figure 1A), a natural bioactive anthracycline, derived
from Aloe barnadensis Miller leaves (also called Aloin AFigure 1 Effect of AL on endothelial cell proliferation in vitro. A, the s
induced HUVECs proliferation in dose-dependent manner as described in “
normal culture condition. Cell viability was quantified by MTT assay. The baor Barbaloin or10-β-D-Glucopyranosyl-1,8-dihydroxy-
3-(hydroxymethyl)-9(10H)-anthracenone;), which was re-
ported to show pharmacological effects, such as
anti-inflammatory, antimicrobial, antioxidant activities,
anti-virus and anti-cancer potential [16]. Studies showed
that AL was able to induce cell cycle arrest and apoptosis
in various human cancer cells, including breast [17], ovar-
ian [18], uterine carcinoma [19], B16-F10 murine melan-
oma [16], and human Jurkat T lymphocytes cells [20].
Moreover, it was also reported to show wonderful healing
and softening properties [21,22], suggesting the potential
role of AL in antiangiogenesis. Therefore, these prompted
us to evaluate the antiangiogenic and anticancer activities
of AL and to fully elucidate its molecular mechanisms
with special focus on STAT3 signaling pathway in human
umbilical vein endothelial cells (HUVECs) and colorectal
cancer cells. In the present study, we report our findings
on human colorectal cancer growth suppressive activities
of AL, its efficacy in inhibiting constitutive STAT3 signal-
ing in vitro, and the effects on the processes of tumor
angiogenesis and growth in vivo.
Materials and methods
Reagents
AL (purity > 97%) was purchased from Sigma (St. Louis,
MO). A 20 mmol/L solution of AL was dissolved in
DMSO, and stored as small aliquots at -20°C.tructure of Aloin. B, treatment with AL significantly inhibited VEGF-
Materials and methods.” C, effects of AL on HUVECs viability under
rs represent triplicate analysis.**, P < 0.01; ***, P < 0.001 vs. control.
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Systems (San Diego, CA). Antibodies against VEGFR2,
STAT3, c-Myc, Bcl-xL, Anti-VEGF, β-actin and
phospho-specific anti-VEGFR2 (Tyr1175) and anti-
STAT3 (Tyr705) were obtained from Santa Cruz
Biotechnology (Santa Cruz, CA).
Cell culture
Human umbilical vascular endothelial cells (HUVECs)
were from Sciencell (Carlsbad, CA, USA) and cultured
in M199 (Invitrogen, Carlsbad, CA) supplemented with
20% fetal bovine serum (FBS). HUVECs were used
within passages three to six. Human colorectal cancer
cell lines (SW620, HCT116) were purchased from the
China Center for Type Culture Collection (Shanghai,
China). The cells were cultured according to the sup-
plier’s instruction, at 37°C, 5% CO2.
Cell viability assay
Briefly, HUVECs (5 × 103 cell/well) were seeded onto
0.1% gelatin coated 96-well plates and allowed to attach
overnight. After being starved for 7–9 h in M199
containing 1% FBS, the cells were exposed to various
concentrations of AL (1, 5, 10, 20 μmol/L ) with or with-
out VEGF (50 ng/mL) for 72 h. Human colorectal cancer
cell lines SW-620 and HCT-116 (4.5 × 103 cells/well)
were directly treated with AL, respectively. Cell viability
was measured by MTT assay. The number of viable cells
in treated wells relative to those in control wells gave
the percentage of inhibition. Experiments were done in
triplicate.
Endothelial cell migration assay
The migratory activity of HUVECs was assessed using
the scratch assay, as previously reported [23]. Briefly, a
narrow area on the confluent HUVECs monolayers in 6-
well plates were scratched off with a p200 pipette tip.
After washing, cells were treated with indicated concen-
trations of AL in M199 with 1% FBS and 50 ng/mL
VEGF. Cells were allowed to migrate for additional 8–9
h, photos were taken from the same areas as those
recorded at zero time and the numbers of the migrated
cells were counted.
Transwell invasion assay
The in vitro cell invasion assay was performed in the 24-
well plates by using a modified Boyden chamber inserts
(8 μm) as described previously with modifications [24].
The filter membranes were coated with Matrigel (BD
Biosciences, San Jose, CA). A single-cell suspension (200
μl serum-free M199 media with 1% FBS) containing 5 ×
104 endothelial cells were treated with AL (1, 5, 10,
20 μmol/L) and loaded into the upper chamber. A 500
μL culture medium (1% FBS, 50 ng/mL VEGF) wasadded to the lower wells of the chamber. After incuba-
tion for 8h at 37°C in 5% CO2, the migrated cells were
fixed and stained with 0.1% crystal violet. Invasiveness
was determined by counting the cells that have migrated
through the filter. Experiments were performed in
triplicates.
Matrigel tube formation assay
HUVECs were harvested with trypsin, resuspended in
300 μl basic endothelial cell culture medium at a density
of 5 × 104 per well and pretreated with AL (1, 5, 10,
20 μmol/L) for 1h with or without VEGF(50 ng/mL) before
plating onto the 48-well unpolymerized Matrigel-coated
plates. After approximately 9–11 hours of incubation at
37°C in 5% CO2, tube formation was photographed and
quantitatively analyzed in randomly chosen microscopic
fields (Nikon; original magnification, ×40), by counting the
number of tube-like structures formed by connecting endo-
thelial cells. The data presented represent the average of
triplicate experiments.
Live/Dead assay
Apoptosis of cells was also determined by Live/Dead
assay (Invitrogen), which was used to measure intracel-
lular esterase activity and plasma membrane integrity as
described elsewhere [15].
Western blotting analysis
To determine molecular mechanism of AL on VEGF-
dependent angiogenesis signaling pathway, western blot
analysis was performed to detect key proteins involved
in the biological functions of endothelial cells and cancer
cells. HUVECs were first starved in serum-free ECM for
7 ~ 9 h and then treated with various concentrations AL
as indicated in the figures, followed by stimulation with
50 ng/mL of VEGF for 5 ~ 20 min. However, tumor cells
were exposed to AL for different duration under the
normal culturing conditions. Total cell lysates prepar-
ation and Western blot analysis were performed
according to the procedure described before [25]. In
brief, equal amounts of protein (40 μg) were resolved on
(6%-12%) SDS-PAGE, electro transferred onto PVDF
membranes, probed with specific antibodies and then
detected by chemiluminescence system detection kit
(Cell Signaling, Beverly, MA).
Subcutaneously Xenografted mouse model
All animal experiments were carried out in accordance
with a protocol approved by the Institutional Animal
Care and Use Committee (IACUC). Briefly, 4 × 106 cells
SW620 cells were implanted to 6-wk-old male athymic
nude mice in the right flank region. After tumors (100–
150 mm3) had established, the mice were randomly
assigned into two treatment groups containing control
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ment of AL for consecutive 27 days. The mice of control
group were administrated with same amount of pure re-
fined corn oil. Tumor volume was determined by measur-
ing the major (L) and minor (W) diameter with a caliper,
and calculated in length × (width2)/2. The tumors were ex-
cised and weighed after termination of experiments.
Histology and immunohistochemistry
Tumor were removed and processed for paraffin embedding.
Immunohistochemical analysis with anti-CD31 antibody and
in situ terminal deoxynucleotidyl transferase dUTP nick end
labeling (TUNEL) staining were applied on the 5-μm sec-
tions. Images were taken using a Leica DM 4000B photo
microscope (Solms, Germany; magnification, 400×).
Statistical analysis
All results are expressed as the mean ± s.d. Statistically
differences between the samples were examined by two-
tailed Student’s test. A P value <0.05 was considered to
be statistically significant.
Results and discussion
Effect of AL on endothelial cells proliferation in vitro
Angiogenesis has been an attractive target for drug therapy
because of its key role in the growth and metastatic spread
of malignant tumor [26]. An extensive array of nature com-
pounds, particularly those present in dietary and medical
plants, have been found to be effective at inhibiting angio-
genesis and cancer cell viability, currently in preclinical de-
velopment [27,28]. Aloe plant, one traditional Chinese
medicine, is generally regarded as a safe dietary supplement
to treat multiple disorders. Aloin, being a natural com-
pound and the main ingredient of aloe, has been docu-
mented for its remarkable potential therapeutic options in
cancer. However, its roles in tumor angiogenesis and the
involved molecular mechanism are unknown.
To systematically address the contribution of suppress-
ing tumor angiogenesis in vitro, we first evaluated the abil-
ity of AL to inhibit the proliferation of HUVECs via the
MTT assay. As shown in Figure 1B, VEGF (50 ng/mL)
stimulation increased the numbers of HUVECs ~3-fold.
AL at a range of concentrations remarkably decreased
VEGF-induced cell viability with the half maximal inhibi-
tory effect at 10 μmol/L in HUVECs when compared with
VEGF stimulation alone after 72 h treatment. However,
these properties were not due to cytotoxicity of AL in
HUVECs, because AL did not show any significant cyto-
toxic effect on HUVECs at dose up to 40 μM under nor-
mal culture conditions (Figure 1C).
Effect of AL on antiangiogenic function in vitro
Chemotactic motility of vascular endothelial cells are im-
portant in the angiogenic sprouting process. To determinethe effects of AL on endothelial cell migration stimulated
by VEGF, we scraped confluent monolayers of HUVECs to
clear space for motile cells to move into. As shown in
Figure 2A, stimulation by VEGF (50 ng/mL) increased
HUVEC motility to nearly fill in the gap after 8 hours of
“wounding” the monolayer, however, AL dose-dependently
inhibited VEGF-induced migration of HUVECs, with max-
imal inhibition concentration at 20 μmol/L. The similar ef-
fects of AL on the invasive potential of HUVECs were
confirmed by the modified Boyden chamber assay, which
required cells to degrade and migrate through a sheet to
extracellular matrix on a Matrigel-coated membrane. Re-
sults showed that VEGF (50 ng/mL) significantly induced a
2-fold increase of endothelial cells invasion in vitro
(Figure 2B), and this effect was markedly impaired by AL
in dose-independent manner (Figure 2B).
We also further evaluated the effect of AL on capillary
differentiation of HUVECs on a layer of Matrigel, focusing
on the concentration range of 1 to 20 μmol/L. As shown
in Figure 2C, endothelial cells differentiate and align to
form a highly branched network of capillary-like struc-
tures in HUVECs after planted 9–10 h late, while AL
treatment (20 μmol/L) caused a significant blockage of the
endothelial tubular structures formation (Figure 2C).
Quantitative analyses revealed such inhibitory effects of
AL were concentration-dependent.
Effect of AL on signaling pathway in HUVECs
Because the STAT3 pathway plays an important role in cell
growth, proliferation, angiogenesis and metastasis et al.,
we hypothesized AL exhibits anti-angiogenenic activity
through blocking STAT3 signaling and next investigated
the effects of AL on the key signaling molecules. Whole-
cell extracts of VEGF-stimulated cells were analyzed by
Western blotting. On ligand stimulation, a marked increase
in phosphorylated STAT3 was observed, indicative of re-
ceptor activation. Moreover, AL dependently inhibited the
VEGF-induced phosphorylation of STAT3 at concentration
with maximum inhibition occurring at 10 μmol/L to
20 μmol/L around 3 h (Figure 3A2). The expression of
total STAT3 protein was not altered by the drug treatment.
In parallel, a rapid down-regulation of VEGFR2 phosphor-
ylation at Tyr 1175 site induced by VEGF (Figure 3A1) was
also verified. The levels of total VEGFR2 kinase remained
constant under the same conditions (Figure 3A).
Previous studies have indicated that nonreceptor pro-
tein tyrosine kinases including JAK2 and Src cooperate
to mediate constitutive activation of STAT3 [13,14]. Al-
though this study did not completely demonstrate the
effect of AL on JAK2 and Src, we anticipate that the de-
activation of STAT3 signaling cascade through suppress-
ing the activation of VEGFR2-mediated c-Src and JAK2
by AL may contribute to tumor angiogenesis inhibition
of colorectal cancer.
Figure 2 Effect of AL on VEGF-induced endothelial migration, invasion and tube formation in vitro. HUVECs were plated to full confluence
on six-well plates. A single scratch was made and cells were treated with VEGF in the presence or absence of AL. A, VEGF stimulation led to an
increase in cell migration after 7 h. AL remarkably reduced numbers of migrated endothelial cells induced by VEGF. The migrated cells were
quantified by direct counting. B, AL inhibited VEGF-induce invasion of HUVECs. Cells were seeded in the upper chamber of Transwell and treated
with different concentrations of AL. Representative images were shown as described in “Materials and methods.” C, tube formation assay on
Matrigel. HUVECs were exposed to different concentration of AL with or without VEGF(50 ng/mL) for 9–10 h. Significant inhibition of endothelial
tubular structures formation was observed in a dose dependent manner. Indexing was performed by counting micro tubes or cell in randomly
selected four different fields. The results shown are representative of four independent experiments.*, P < 0.05; **, P < 0.01; ***, P < 0.001
vs. control.
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To determine whether inhibiting the activation of
STAT3 would have a direct antineoplastic activity on
cancer cells, we next tested its effect of AL on constitu-
tive STAT3 phosphorylation in SW620 cancer cells.
Treatments with AL at indicated concentrations were
found to induce down-regulation of phospho-STAT3 in
dose-dependent manner but had no impact on total
STAT3 expression (Figure 3B1).
As previously mentioned, the STAT3 signaling has been
identified to be important in cell survival, proliferation
and apoptosis escape of numerous cancers [14].We further
investigated whether the expression of STAT3-regulated
target gene products was modulated by AL in SW620 cells
for various time periods. As the results here presented,
three key antiapoptotic (Bcl-xL), pro-proliferation (c-Myc)
and angiogenic genes (VEGF) were significantly reducedin response to AL (200 μmol/L), with maximum suppres-
sion observed at around 48 to 72 h (Figure 3B2).
Bcl-xL has been reported to block cell death induced
by a variety of chemotherapeutic agents [29,30] and
commonly confers chemoresistance [31]. Thus, down-
regulation of the levels of antiapoptotic (Bcl-xL) and
proliferative (c-Myc) proteins products are likely linked
with AL’s ability to induce apoptosis, proliferation inhib-
ition and cell cycle arrest in tumor cells. Our findings
reported here are similar with previous studies
[16,17,20]. In addition, our results also showed that AL
treatment could inhibit the secretion of VEGF by cancer
cells. VEGF, is one of the most important pro-angiogenic
cytokines known and well characterized inducers in
tumor neovascularization. The course of the down-
regulation of apoptosis- and angiogenesis-related genes
by AL might be explained through blocking STAT3
Figure 3 Effect of AL on STAT3 Pathway in both HUVECs and SW620 cancer cells. A(A1), AL suppressed the activation of VEGFR2 triggered
by VEGF in endothelial cell. (A2), inhibition pospho-VEGFR2 resulted in a diminished activation of STAT3 in endothelial cells in dose dependent
manner. HUVECs were first starved in serum-free ECM for 7–9 h and then pretreated with AL at various concentrations for periods with or
without VEGF(50 ng/mL) for 5 ~ 20 min. Total VEGFR2 and STAT3 verified equal protein loading by Western blotting, as described in “Material and
Methods.” B(B1), AL suppressed phospho-STAT3 levels in SW620 cell line in a dose manner. Tumor cells were directly treated with the indicated
concentration of AL for different duration. The same blots were stripped and reprobed with STAT3 antibody to verify equal protein loading. (B2),
AL(200 μmmol/L) suppresses STAT3-regulated genes products (Bcl-xL c-Myc and VEGF) in SW620 cells in time-dependently. β-actin was used as
an corresponding internal control to show equal protein loading.
Figure 4 Effect of AL on proliferation inhibition and apoptosis induction in colorectal cancer in vitro. A, AL significantly suppressed the
proliferation of both SW620 and HCT116 cell lines evaluated by MTT assay as described under “Materials and methods”. B, Degree of AL-induced
apoptosis in SW620 cell lines were determined by Live/Dead assay. Data are presented as relative increase in apoptosis of treated cells compared
with untreated control cells. Similar results were obtained in three independent experiments.*, P < 0.05; **, P < 0.01 vs. control.
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tween angiogenesis and tumor growth.
Effect of AL on cell viability inhibition and apoptosis
induction of colorectal cancer cell lines in vitro
Because AL treatment affected the activation of STAT3
and STAT3-regulated gene products important for cell
survival and apoptosis, we next assessed whether it
inhibited the proliferation of tumor cells. Following a 72
h exposure to AL, two CRC cell lines displayed similar
sensitivity. As shown in Figure 4A, AL exhibited cell via-
bility suppression on SW620 (Figure 4A1) and HCT116
cells (Figure 4A2) in vitro, with an IC50 values ranging
from 200 μmol/L-240 μmol/L. When we further
employed Live-Dead staining assay, our results showed
that there was a marked increase in apoptosis as com-
pared to control in a dose-dependent manner. The pro-
portion of apoptotic cells were accordingly increased
from 2.71% to 36.5% in SW-620 cells after 72 h exposure
to AL (120 μM, 200 μM) (Figure 4B1).
In current study, our data showed that AL significantly
inhibited in vitro VEGF-induced angiogenic response of
human endothelial cells, to inhibit proliferation andFigure 5 Effect of AL on tumor growth arrest and angiogenesis inhib
dosages of 20 mg/kg was initiated when tumor volumes reached approxim
resulted in tumor growth inhibition of 63% at day 27 as measured by tumo
amount of pure refined corn oil served as vehicle controls. D, Immunohisto
CD31-positive blood vessels and induced apoptosis in human colorectal camigration of endothelial cells, and to reduce the ability to
form capillary vessel, with maximum inhibition dose ob-
served at 10 μmol/L to 20 μmol/L. When compared the
effective concentrations of AL on endothelial cells
(Figures 1 and 2, 10 ~ 20 μmol/L) and colorectal tumor
cells (Figure 4A, 200 ~ 240 μmol/L), we found that AL
might conceivably affect tumor-induced angiogenesis
in vitro at local concentration much lower than those ne-
cessary to cause a cytotoxic effect on cancer cells, indicat-
ing that AL is more effective in angiogenesis disease
condition. The anti-angiogenesis mediated by AL on
endothelial cells may be earlier than a direct cytotoxic
effect on tumor cells.
The antitumor effects of AL in vivo
In the present study, human SW620 CRC nude mouse
xenograft model was well performed to validate our re-
sults in vitro. As shown in Figure 5A and B, treatment
of SW620 tumor-bearing animals (n = 6) at 20 mg/kg/d
body weight, oral gavage, once daily, resulted in growth
inhibition of 63% at day 27. There was no significant
weight loss (Figure 5C) or other signs of acute or de-
layed toxicity (data not shown) compared to controls,ition in SW620-bearing mice. Daily oral treatment with AL at
ately 120 mm3, as described in “Materials and methods.” A-C, AL
r volume and weight with little toxicity at the tested dose. Same
chemical and TUNEL analysis showed that AL inhibited numbers of
ncer xenografts. Original magnification, ×400. **, P < 0.01 vs. control.
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ment system, both high and low dosages of AL were also
tested; however, 10 mg/kg of AL did not effectively in-
hibit tumor volume and 30mg/kg of AL showed some
toxic effect on the body weight of mice.
We next performed immunohistochemistry with anti-
CD31 antibody and TUNEL analysis on tumor sections
from xenografted mice with or without the treatment of
AL. Immunostaining revealed large numbers of CD31-
positive blood vessels throughout the tumor of untreated
mice, whereas fewer CD31-positive vessels were found
in AL-treated tumors (Figure 5D, left). Additionally,
apoptotic cells were increased in AL-treated group as in-
dicated by TUNEL analysis (Figure 5D, right). Consistent
with previous results observed in vitro and in vivo, our
data supported our hypothesis that AL can cooperate to
suppress tumor growth of human colorectal cancer xe-
nografts by exerting a primary anti-angiogenic activity
on endothelial cells at lower concentrations (below 20
μM) and a direct apoptotic effect on tumor cells at
higher concentrations (up to 200 μM) through STAT3
signaling pathway.
Conclusion
AL may represents one safe, affordable and orally active
drug applied in clinical practice for cancer prevention
and therapy, even at high doses. In the future, experi-
mental as well as clinical studies e.g. regarding the com-
bination of AL and conventional chemotherapeutics will
further elucidate its therapeutic value in human colorec-
tal cancer.
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